Drug Approval | August 16, 2023
Eugia Pharma receives USFDA Approval for Icatibant Injection
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
Granules now have a total of 53 ANDA approvals from USFDA
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
Subscribe To Our Newsletter & Stay Updated
